Abstract
Functional abdominal pain syndrome (FAPS) is a distinct chronic gastrointestinal (GI) pain disorder characterized by the presence of constant or frequently recurring abdominal pain that is not associated with eating, change in bowel habits, or menstrual periods. The pain experience in FAPS is predominantly centrally driven as compared to other chronic painful GI conditions such as inflammatory bowel disease and chronic pancreatitis where peripherally acting factors play a major role in driving the pain. Psychosocial factors are often integrally associated with the disorder and can pose significant challenges to evaluation and treatment. Patients suffer from considerable loss of function, which can drive health care utilization. Treatment options are limited at best with most therapeutic regimens extrapolated from pain management of other functional GI disorders and chronic pain conditions. A comprehensive approach to management using a biopsychosocial construct and collaboration with pain specialists and psychiatry is most beneficial to the management of this disorder.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Clouse RE, Mayer EA, Aziz Q, et al. Functional abdominal pain syndrome. Gastroenterology. 2006;130:1492–7.
Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38:1569–80.
Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig Dis Sci. 2002;47:225–35.
Sperber AD, Shvartzman P, Friger M, Fich A. Unexpectedly low prevalence rates of IBS among adult Israeli Jews. Neurogastroenterol Motil: Off J Eur Gastrointest Motil Soc. 2005;17:207–11.
Nyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther. 2007;26:237–48.
Longstreth GF, Drossman DA. Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs. Clin Gastroenterol Hepatol. 2005;3:397–400.
Spiegel B, Schoenfeld P, Naliboff B. Systematic review: the prevalence of suicidal behaviour in patients with chronic abdominal pain and irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:183–93.
Grover M, Drossman DA. Functional abdominal pain. Curr Gastroenterol Rep. 12: 391–8.
Coderre TJ, Katz J. Peripheral and central hyperexcitability: differential signs and symptoms in persistent pain. Behav Brain Sci. 1997;20:404–19. discussion 35–513.
Nozu T, Kudaira M. Altered rectal sensory response induced by balloon distention in patients with functional abdominal pain syndrome. Biopsychosoc Med. 2009;3:13.
Melzack R, Coderre TJ, Katz J, Vaccarino AL. Central neuroplasticity and pathological pain. Ann N Y Acad Sci. 2001;933:157–74.
• Sperber AD, Morris CB, Greemberg L, et al. Development of abdominal pain and IBS following gynecological surgery: a prospective, controlled study. Gastroenterology. 2008;134:75–84. An important study showing development of chronic pain in patients undergoing abdominal surgery in the absence of any preoperative pain.
Longstreth GF, Preskill DB, Youkeles L. Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome. Dig Dis Sci. 1990;35:1285–90.
Jess P, Jess T, Beck H, Bech P. Neuroticism in relation to recovery and persisting pain after laparoscopic cholecystectomy. Scand J Gastroenterol. 1998;33:550–3.
Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 1993;52:259–85.
Melzack RWP. Gate-control and other mechanisms. In: Melzack RWP, editor. In the challenge of Pain. London: Pelican Books; 1988. p. 165–93.
Dengler-Crish CM, Bruehl S, Walker LS. Increased wind-up to heat pain in women with a childhood history of functional abdominal pain. Pain. 2011;152:802–8.
Drossman DA, Whitehead WE, Toner BB, et al. What determines severity among patients with painful functional bowel disorders? Am J Gastroenterol. 2000;95:974–80.
Mertz HR. Altered CNS processing of visceral pain in IBS. In: Camilleri M SR, (ed.). Irritable Bowel Syndrome: Diagnosis and Treatment. London: Saunders, 2002, p. 55–68.
Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology. 2000;118:842–8.
Naliboff BD, Derbyshire SW, Munakata J, et al. Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med. 2001;63:365–75.
Drossman DA, Ringel Y, Vogt BA, et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology. 2003;124:754–61.
Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut. 2005;54:601–7.
Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 1997;8:1057–61.
• Dorn SD, Meek PD, Shah ND. Increasing frequency of opioid prescriptions for chronic abdominal pain in US outpatient clinics. Clin Gastroenterol Hepatol. 2011;9:1078–85 e1. Important recent analysis showing increasing opioid use among patients with chronic abdominal pain.
Drossman DA, Talley NJ, Leserman J, Olden KW, Barreiro MA. Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Ann Intern Med. 1995;123:782–94.
Levy RL, Olden KW, Naliboff BD, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology. 2006;130:1447–58.
• Sperber AD, Drossman DA. Functional abdominal pain syndrome: constant or frequently recurring abdominal pain. Am J Gastroenterol. 2010;105:770–4. Rome foundation algorithm on diagnosis of functional abdominal pain syndrome.
• Srinivasan R, Greenbaum DS. Chronic abdominal wall pain: a frequently overlooked problem. Practical approach to diagnosis and management. Am J Gastroenterol. 2002;97:824–30. Important review on an underdiagnosed cause of chronic abdominal pain for which effective treatment can be easily provided.
•• Grunkemeier DM, Cassara JE, Dalton CB, Drossman DA. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol. 2007;5:1126–39. quiz 1–2. Landmark review article on narcotic bowel syndrome.
Gray DW DJ, Collin J. The Closed eyes sign: an aid to diagnosing non-specific abdominal pain. Bmj. 1988; 297.
Lindsetmo RO, Stulberg J. Chronic abdominal wall pain–a diagnostic challenge for the surgeon. Am J Surg. 2009;198:129–34.
Grover M, Drossman DA. Centrally acting therapies for irritable bowel syndrome. Gastroenterol Clin North Am. 40: 183–206.
• Grover M, Drossman DA. Psychopharmacologic and behavioral treatments for functional gastrointestinal disorders. Gastrointest Endosc Clin N Am. 2009;19:151–70. vii-viii. Comprehensive review article on centrally acting agents for tretament of IBS and other functional GI disorders.
Grover M, Drossman DA. Psychotropic agents in functional gastrointestinal disorders. Curr Opin Pharmacol. 2008;8:715–23.
• Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009;58:367–78. Recent meta-analysis showing efficacy of centrally acting treatments in functional GI disorders.
Thiwan S, Drossman DA, Morris CB, et al. Not all side effects associated with tricyclic antidepressant therapy are true side effects. Clin Gastroenterol Hepatol. 2009;7:446–51.
Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007;56:1218–25.
Gale JD, Houghton LA. Alpha 2 Delta (alpha(2)delta) Ligands. Gabapentin and Pregabalin: What is the Evidence for Potential Use of These Ligands in Irritable Bowel Syndrome. Front Pharmacol. 2011;2:28.
Gottsegen D. Hypnosis for functional abdominal pain. Am J Clin Hypn. 2011;54:56–69.
Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 2003;124:303–17.
Drossman DA. Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol. 2009;104:2897–902.
Grover M, Dorn SD, Weinland SR, Dalton CB, Gaynes BN, Drossman DA. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig Dis Sci. 2009;54:1284–91.
Acknowledgment
The author would like to thank Dr. Douglas A Drossman for his guidance and important insights on this topic.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grover, M. When is Irritable Bowel Syndrome Not Irritable Bowel Syndrome? Diagnosis and Treatment of Chronic Functional Abdominal Pain. Curr Gastroenterol Rep 14, 290–296 (2012). https://doi.org/10.1007/s11894-012-0270-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11894-012-0270-8